Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery (ASPIRE)
Clinical Trial Details
This study aims to determine if apixaban is superior to aspirin for prevention of stroke or hemorrhage or death in patients with recent intracerebral hemorrhage or atrial fibrillation.
Key Eligibility:
Men and women 18 years or older, diagnosed with intracerebral hemorrhage and atrial fibrillation.
No known allergy to aspirin or apixaban
Detailed eligibility will be reviewed when you contact the study team
